SCH772984

• CAT Number: I005598
• CAS Number: 942183-80-4
• Molecular Formula: C₃₃H₃₃N₉O₂
• Molecular Weight: 587.67
• Purity: ≥95%
• Target: MEK1/2
• Solubility: DMSO: ≥ 51 mg/mL
• Storage: 3 years -20C powder
• IC50: 4 nM/1 nM (ERK1/2)
• InChI: InChI=1S/C33H33N9O2/c43-30(42-18-16-41(17-19-42)27-5-2-24(3-6-27)32-35-11-1-12-36-32)22-40-15-10-25(21-40)33(44)37-26-4-7-29-28(20-26)31(39-38-29)23-8-13-34-14-9-23/h1-9,11-14,20,25H,10,15-19,21-22H2,(H,37,44)(H,38,39)/t25-/m1/s1
• InChIKey: HDAJDNHIBCDLQF-RUZDIDTESA-N
• SMILES: C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7

SCH772984 (CAT: I005598) is a potent and selective inhibitor of mitogen-activated protein kinase (MAPK) signaling, particularly targeting extracellular signal-regulated kinase (ERK) 1/2. It inhibits the phosphorylation of ERK1/2 and disrupts downstream signaling cascades involved in cell proliferation and survival. SCH772984 has shown efficacy in preclinical models of various cancers, including melanoma, pancreatic cancer, and non-small cell lung cancer. Its selective targeting of the ERK pathway makes it a promising candidate for targeted therapy, and further studies are underway to evaluate its clinical potential in cancer treatment.

Reference

1:Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain. Bian J, Zhu S, Ma W, Li C, Ashraf MA.Saudi Pharm J. 2016 May;24(3):354-62. doi: 10.1016/j.jsps.2016.04.017. Epub 2016 Apr 26. PMID: 27275127 Free PMC Article
2:Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A.Mol Cancer. 2014 Aug 20;13:194. doi: 10.1186/1476-4598-13-194. Erratum in: Mol Cancer. 2015;14:128. PMID: 25142146 Free PMC Article